Yes. Step 1 of the ECS Administrative Specification Rate 1 should say, “…who had NO cervical cytology.”
This will be corrected in the next release of the manual.
FAQ Directory
Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can ask a question through My NCQA.
Filter Results
-
Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
-
Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
-
Print
Print this page.
Print this page.
1.24.2014
Evidence-Based Cervical Cancer Screening of Average-Risk Asymptomatic Women (ECS) Step 1 of the ECS Administrative Specification Rate 1 states, “Identify the number of women 24–65 years of age with hysterectomies who had cervical cytology.”
In the MY 2012 P4P manual, step 1 of Rate 1 in the ECS Administrative Specification says, “…who had NO Pap tests.” Should the text in the MY 2013 P4P Manual say, “who had NO cervical cytology”?
1.24.2014 Proportion of Days Covered by Medications (PDC) The Oral Diabetes Tab includes the NDC code 47463051060, which may be incorrectly assigned to a GCN. This NDC (47463051060—metformin) is assigned to GCN 71160. However, for other NDCs with the same generic drug name (metformin), route and GPI are assigned to GCN 89863. Which GCN is correct?
The NDC code 47463051060 (Metformin HCl Tab SR 24HR 500 MG) is incorrectly assigned to GCN 71160. The correct GCN is 89863.
This particular NDC was recycled to the medication metformin and therefore should have a GCN of 89863, rather than the previous GCN linked to the obsolete NDC.
This applies to the following Programs and Years:
IHA P4P1.15.2014 Distribution of the Member's Rights and Responsibilities Statement May a delegate distribute the statement of members' rights and responsibilities?
1.15.2014 Board Certification as Verification of Education and Training for Nurse Practitioners (NP) and Physician Assistants (PA) Is it acceptable to use ANCC and NCCPA board certification as verification of highest level of education for nurse practitioners and physician assistants?
12.20.2013 Asthma Medication Ratio (AMR) Step 1 in the Event/Diagnosis section of the Eligible Population criteria refers to Table ASM-C for identifying asthma medication dispensing events. There is no Table ASM-C in the specification.
12.20.2013 Controlling Blood Pressure for People with Hypertension (CBPH) The CBPH measure is not listed in the P4P Value Set Directory. Where can we find the Value Sets for this measure?
The CBPH Value Sets can be found by filtering for Value Set Name in the P4P Value Sets to Codes tab of the P4P VSD file. The Value Sets for CBPH already exist as part of the CDC measure. The next release of the Value Set Directory will list the CBPH measure separately.
This applies to the following Programs and Years:
IHA P4P
12.20.2013
Evidence-Based Cervical Cancer Screening of Average-Risk, Asymptomatic Women (ECS) Step 3 of Rate 2 Underscreened does not specify what to do with the remaining population of women 30- 65 years with no hysterectomy who have no cervical cytology tests in the measurement year or two years prior to the measurement year and EITHER:
• Zero cervical cytology and HPV co-tests OR
• Two or more cervical cytology and HPV co-tests in the three or four years prior to the measurement year.
Could you clarify?
12.20.2013 Supplemental Data Guidelines Have the dates been extended for primary source verification and final approval of supplemental data for P4P Measurement Year 2013?
Yes. Data collection and entry of all nonstandard and member-reported supplemental data must stop on March 3. Primary source verification and final approval must be completed by March 14, for member-reported supplemental data, and by March 28, for nonstandard supplemental data. Primary source verification may not occur before March 3 unless all supplemental data processes, collection and entry have stopped. Supplemental data approval and primary source verification may not occur, under any circumstances, before January 1 and receipt of the Roadmap.
This applies to the following Programs and Years:
IHA P4P12.16.2013 General Guidelines Are HbA1c and LDL-C tests where the member collects a blood sample at home and sends it to a lab for results calculation allowed for HEDIS reporting?
12.16.2013 Cervical Cancer Screening In step 2 of the Administrative Specification, organizations identify women 30-64 years of age as of December 31 of the measurement year who had cervical cytology and a human papillomavirus (HPV) test, with service dates four or less days apart during the measurement year. When counting service dates, is the date of the cervical cytology considered day one or day zero of the four-day count?
The date of the cervical cytology is considered day zero. For example, if the service date for cervical cytology was December 1 of the measurement year, the HPV test must include a service date on or between December 1 and December 5 of the measurement year.
This applies to the following Programs and Years:
HEDIS 201412.16.2013 General Guidelines If an organization finds an undated lab result in a progress note, can the progress note date be used as the lab result date?
No. An undated lab result may not be used for HEDIS reporting. To be eligible for use, the date the test was performed (e.g., the date the sample was drawn) or the result date (e.g., the date the lab calculated the result) must be documented.
This applies to the following Programs and Years:
HEDIS 201412.16.2013 Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life Is a BMI growth chart sufficient for the physical requirement of the developmental history component?
No. Growth charts (height, weight, BMI or BMI percentile) do not meet criteria for physical developmental history for the W34 measure. The intent of the developmental history component (physical and mental) is to determine if the child was assessed for specific age-appropriate physical and mental developmental milestones, which are behaviors or physical skills seen in children as they grow and develop. For the W34 measure, examples of mental developmental milestones include ability to speak understandably, identify colors and define words appropriately. For the W34 measure, examples of physical developmental milestones include the ability to hop, throw a ball, draw and make a block tower. Documentation of "developing appropriately" or "normal development" meets criteria for both physical and mental development. Documentation of "growing appropriately" (without notation about "development") does not meet criteria for physical or mental developmental history.
Additional examples can be found in the Appendices of the Bright Futures Pocket Guide Guidelines for Health Supervision of Infants, Children, and Adolescents (http://brightfutures.aap.org/pdfs/bf3%20pocket%20guide_final.pdf).